Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Effect of sitravatinib combined with PD-1 blockade on cytotoxic T-cell infiltration by M2 to M1 tumor macrophage repolarization in esophageal adenocarcinoma.
Authors
Ashten Omstead
Allegheny Health Network Cancer Institute, Allegheny Health Network, Pittsburgh, PA
Ashten Omstead , Ping Zheng , Ryan Sweeny , Anastasia Gorbunova , Arul Goel , Patrick Wagner , Ronan Joseph Kelly , Blair A Jobe , Ali Hussainy Zaidi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Translational Research
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 383)
DOI
10.1200/JCO.2024.42.3_suppl.383
Abstract #
383
Poster Bd #
J6
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Phase II study of sitravatinib in combination with nivolumab in patients undergoing nephrectomy for locally-advanced clear cell renal cell carcinoma (ccRCC).
First Author: Jose A. Karam
Poster
2018 ASCO Annual Meeting
Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).
First Author: Shubham Pant
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated MSS/MSI-low metastatic colorectal cancer (mCRC): The randomized phase 3 STELLAR-303 study.
First Author: Anwaar Saeed
Poster
2023 ASCO Genitourinary Cancers Symposium
Differential expression of PDL-1 and tumour-associated macrophages in N0 and N+ penile cancer.
First Author: Fowz Azhar